Omvoh Kit
Product Images NDC 0002-7717

Product Visual Gallery

This gallery contains 65 technical images submitted to the FDA as part of the official labeling for Omvoh (NDC 0002-7717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Omvoh 100mg Ai 1 V2)

Image of two Omvoh (mirikizumab-mrkz) injection devices for subcutaneous use. The devices are white with blue caps and feature locking mechanisms indicated by lock and unlock icons. No specific strength or other labeling details are visible on the devices. Manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Omvoh 100mg Ai 2 V2)

An instructional diagram showing the components of the Omvoh (mirikizumab-mrkz) 100 mg/mL subcutaneous injection device. It highlights the blue injection button, lock ring with lock/unlock symbols, medicine area, needle, clear base, and gray base cap. The image illustrates how two 100 mg/mL units combine to make one full dose.*

FDA Label Image

Figure (Omvoh 100mg Ai 3 V2)

An instructional diagram showing a subcutaneous injection device, likely an auto-injector pen, for the drug Omvoh (mirikizumab-mrkz). The image highlights a specific area on the device's body, possibly indicating a feature or step in use.*

FDA Label Image

Figure (Omvoh Ifu Injection Sites V2)

An anatomical illustration showing recommended injection sites for a subcutaneous injection. Highlighted areas include the back of the upper arm, the abdomen, and the front of the thigh, depicted on front and back views of a human figure.*

FDA Label Image

Figure (Omvoh 100mg Ai 4 V2)

The image depicts a clear glass prefilled syringe labeled Omvoh containing mirikizumab-mrkz injection for subcutaneous use. The syringe is marked with measurement lines and has a blue stopper. Eli Lilly and Company is the labeler. No strength or additional text is visible on the syringe.*

FDA Label Image

Figure (Omvoh 100mg Ai 5 V2)

An instructional illustration depicting how to remove the gray base cap from a subcutaneous injection device labeled Omvoh. The image shows two hands; one holding the injection pen and the other twisting the gray base cap off, with arrows indicating the direction of removal. The needle is also labeled in the diagram.*

FDA Label Image

Figure (Omvoh Ai Lock)

FDA Label Image

Figure (Omvoh 100mg Ai 6 V2)

Instructional illustration showing the use of Omvoh (mirikizumab-mrkz) injection. It depicts a person administering a subcutaneous injection to the abdomen using a pen device. The pen has a clear base and a blue cap, with an inset detail indicating how to remove or twist the cap before injection.*

FDA Label Image

Figure (Omvoh Ai Unlock)

FDA Label Image

Figure (Omvoh 100mg Ai 7 V2)

An instructional illustration showing a hand administering a subcutaneous injection in the abdominal area. The image includes a timer icon indicating to wait 10 seconds during or after the injection process.*

FDA Label Image

Figure (Omvoh 100mg Ai 8 V2)

An instructional diagram showing a close-up view of the bottom part of a prefilled syringe or injection device for Omvoh (mirikizumab-mrkz). It highlights the gray plunger with an arrow and label.*

FDA Label Image

Figure (Omvoh 100mg Ai 9 V2)

An instructional illustration showing a hand disposing of a used prefilled syringe into a red sharps container, demonstrating safe disposal of the Omvoh injection device.*

FDA Label Image

Figure (Omvoh Qr V1)

FDA Label Image

Figure (Omvoh 100mg Pfs 1)

The image shows two prefilled syringes of Omvoh (mirikizumab-mrkz) subcutaneous injection in solution form. Each syringe has a white barrel and a blue plunger, designed for human prescription use. No additional labeling or strength markings are visible on the syringes themselves.*

FDA Label Image

Figure (Omvoh 100mg Pfs 2 V2)

Illustration of the Omvoh injection device showing a labeled diagram of the syringe components, including blue thumb pad and plunger rod, finger grips, gray syringe plunger, syringe body with medicine, needle, and needle cap. The bottom note states that two 100 mg/mL injections equal one full dose.*

FDA Label Image

Figure (Omvoh 100mg Pfs 3)

An instructional diagram showing a subcutaneous injection device with an arrow pointing to a section near the needle or cap, likely indicating a step or important feature. The device has a blue plunger and a white barrel.*

FDA Label Image

Figure (Omvoh 100mg Pfs 4)

An instructional diagram showing hands preparing a prefilled syringe for injection. The left hand holds the syringe, while the right hand is shown pulling off a cap from the syringe needle, indicated by a red arrow pointing away from the syringe.*

FDA Label Image

Figure (Omvoh 100mg Pfs 5)

An instructional illustration showing a hand administering a subcutaneous injection at a 45-degree angle into the skin. The image highlights the correct needle insertion angle between 45 and 90 degrees for proper injection technique.*

FDA Label Image

Figure (Omvoh 100mg Pfs 6)

Illustration showing a person administering a subcutaneous injection using a prefilled syringe with a blue cap. The image depicts a hand holding the syringe and injecting into the skin, indicated by a red downward arrow highlighting the direction of the injection.*

FDA Label Image

Figure (Omvoh 100mg Pfs 7)

An illustration showing a cross-section of a syringe with labels identifying the blue plunger rod and gray syringe plunger. The image highlights components of the syringe used for injecting Omvoh (mirikizumab-mrkz) injection, solution, subcutaneous.*

FDA Label Image

Figure (Omvoh 100mg Pfs 8)

An instructional illustration showing a hand holding a syringe with a blue plunger cap, positioned above a red sharps disposal container with a white lid. The image depicts the proper disposal of the syringe after use for the medication Omvoh (mirikizumab-mrkz) injection, solution for subcutaneous administration.*

FDA Label Image

Figure (Omvoh 300mg Pen 1 V1)

An instructional diagram showing two views of a prefilled injection pen device for the subcutaneous administration of Omvoh (mirikizumab-mrkz). The pen has a white body, a blue cap on top, and a gray base. Numbered steps and lock/unlock icons are visible, likely indicating how to use or prepare the device for injection.*

FDA Label Image

Figure (Logo)

FDA Label Image

Figure (Omvoh 300mg Pen 2 V1)

Illustration showing a subcutaneous injection pen for Omvoh (mirikizumab-mrkz) with labeled parts including the blue injection button, lock ring, lock or unlock symbols, medicine chamber, needle, clear base, and a removable gray base cap with orientation arrows. The diagram indicates top and bottom needle ends.*

FDA Label Image

Figure (Omvoh 300mg Pen 3 V1)

An illustration showing the location of the expiration date on a prefilled syringe of Omvoh (mirikizumab-mrkz) injection, solution, subcutaneous use, manufactured by Eli Lilly and Company. The expiration date is indicated on the syringe barrel, emphasized with a red circle and arrow.*

FDA Label Image

Figure (Omvoh 300mg Ifu Injection Sites Front V1)

An illustration showing suggested subcutaneous injection sites on a human body for Omvoh (mirikizumab-mrkz) injection, solution. Highlighted sites include the abdomen around the navel and both front thigh areas.*

FDA Label Image

Figure (Omvoh 300mg Ifu Injection Sites Back V1)

An instructional diagram showing recommended injection sites for Omvoh (mirikizumab-mrkz) solution for subcutaneous injection. Blue patches indicate the outer area of the upper arms on both sides as suitable injection locations.*

FDA Label Image

Figure (Omvoh 300mg Pen 4 V1)

Illustration showing the proper removal of the gray base cap from an Omvoh injection pen labeled with mirikizumab-mrkz. The diagram highlights the needle and gray base cap, demonstrating the cap's counterclockwise removal by hand, relevant for subcutaneous injection preparation.*

FDA Label Image

Figure (Omvoh 300mg Pen 5 V1)

An instructional diagram of an injection pen featuring a blue cap and a scale indicator. The image focuses on usage steps or device operation, showing numbered steps and a lock/unlock icon, guiding the user on proper injection technique with the pen.*

FDA Label Image

Figure (Omvoh 300mg Pen 6 V1)

An instructional diagram showing the subcutaneous injection of Omvoh (mirikizumab-mrkz) using a syringe device. The image highlights a clear base on the device and includes an inset detail indicating a rotating or locking mechanism on the syringe.*

FDA Label Image

Figure (Omvoh 300mg Pen 7 V1)

An instructional illustration showing a hand holding an Omvoh prefilled injection device against the abdomen, with an arrow indicating insertion and a timer icon displaying 15 seconds, likely representing the recommended duration to hold the injection in place during subcutaneous administration.*

FDA Label Image

Figure (Omvoh 300mg Pen 8 V1)

An instructional diagram highlighting a component labeled as 'Gray Plunger' on a syringe or injection device. The gray plunger area is circled and indicated by an arrow to show its position within the syringe mechanism.*

FDA Label Image

Figure (Omvoh 300mg Pen 9 V1)

An instructional illustration showing a hand disposing of a used prefilled syringe labeled for subcutaneous injection into a red sharps container, emphasizing safe disposal practices for the injection device.*

FDA Label Image

Figure (Omvoh 300mg Pfs 1 V1)

Omvoh (mirikizumab-mrkz) injection solution in a prefilled syringe for subcutaneous use. The image shows two clear plastic syringes with blue plunger handles and protective flanges near the needle area, consistent with injectable drug delivery devices. Manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Omvoh 300mg Pfs 2 V1)

An instructional diagram showing a subcutaneous injection device for the drug Omvoh (mirikizumab-mrkz). The diagram labels parts including the blue plunger rod with thumb pad, finger grips, gray syringe plunger inside the syringe body containing medicine, needle with needle cap, and depicts both top and bottom views of the device.*

FDA Label Image

Figure (Omvoh 300mg Pfs 3 V1)

An instructional diagram highlighting the location of the expiration date on a prefilled syringe used for subcutaneous injection. The expiration date is indicated by an arrow pointing to a specific area on the syringe barrel.*

FDA Label Image

Figure (Omvoh 300mg Pfs 4 V1)

Illustration showing hands preparing a prefilled syringe for subcutaneous injection. One hand holds a syringe labeled Omvoh, pulling back the plunger, while the other hand holds the needle cap with an arrow indicating the direction to remove the cap.*

FDA Label Image

Figure (Omvoh 200mg Pfs 5)

An instructional illustration showing the correct technique for subcutaneous injection of Omvoh (mirikizumab-mrkz). It depicts a hand holding a syringe at a 45-degree angle to the skin, indicating the proper angle for administering the injection.*

FDA Label Image

Figure (Omvoh 300mg Pfs 6 V1)

An instructional illustration showing a hand pressing a blue button on a prefilled injection device inserted subcutaneously into an abdomen, with a red arrow indicating pressing or activating the device for subcutaneous injection.*

FDA Label Image

Figure (Omvoh 300mg Pfs 7 V1)

An instructional diagram of a syringe showing the blue plunger rod and gray syringe plunger labeled with arrows. The syringe appears to be for subcutaneous injection.*

FDA Label Image

Figure (Omvoh 300mg Pfs 8 V1)

An instructional illustration showing a hand holding a syringe-like injector device and placing it into a sharps disposal container, demonstrating the proper disposal method for the injection device after use.*

FDA Label Image

Figure (Omvoh 200mg Pen 1)

Omvoh 100 mg/mL injection solution in a single-use prefilled syringe for subcutaneous administration. The label includes minimal text and colored markings, with Eli Lilly and Company as the labeler. The syringe container design is visible, including the plunger and needle cover.*

FDA Label Image

Figure (Omvoh 200mg Pen 2)

An instructional illustration of the Omvoh injection pen showing components including the blue injection button at the top, a lock ring with lock/unlock symbols, the medicine chamber, needle, clear base, and a separate gray base cap at the bottom. Directional arrows indicate top and needle end orientation.*

FDA Label Image

Figure (Omvoh 200mg Pen 3)

An illustration showing a subcutaneous injection pen for Omvoh (mirikizumab-mrkz). The image highlights the location of the expiration date on the injector pen with an arrow pointing to the label area where the expiration date is printed.*

FDA Label Image

Figure (Omvoh 200mg Pen 4)

An instructional diagram showing steps for preparing or administering the Omvoh injection solution. The image includes a needle and measurement indicators, indicating proper use of the subcutaneous injection device for the medication mirikizumab-mrkz by Eli Lilly and Company.*

FDA Label Image

Figure (Omvoh 200mg Pen 5)

Instructional illustration showing a hand holding an Omvoh injection pen pointing downward. The image highlights removal of the gray base cap by rotating it in the direction of a red arrow to expose the needle for subcutaneous administration.*

FDA Label Image

Figure (Omvoh 200mg Pen 6)

An instructional illustration showing the use of Omvoh injection, solution for subcutaneous administration. The image highlights rotating a blue cap on the injector device and positioning the clear base of the injector against the skin for proper injection.*

FDA Label Image

Figure (Omvoh 200mg Pen 7)

An instructional diagram showing the correct use of a subcutaneous injection device for Omvoh (mirikizumab-mrkz). It depicts a hand holding the injection pen at a right angle to the abdomen with an arrow pointing to the injection site and a time indicator emphasizing a 15-second wait during administration.*

FDA Label Image

Figure (Omvoh 200mg Pen 8)

An instructional diagram showing a gray plunger component of a syringe or injection device, with a red arrow and label pointing to the gray plunger part.*

FDA Label Image

Figure (Omvoh 200mg Pen 9)

Illustration showing a hand safely disposing of a used prefilled syringe labeled Omvoh (mirikizumab-mrkz) into a red sharps disposal container. The syringe appears to be for subcutaneous injection.*

FDA Label Image

Figure (Omvoh 200mg Pfs 1)

The image shows a syringe prefilled with liquid medication. The syringe has a transparent barrel and a blue plunger handle. This device is likely for subcutaneous injection, consistent with Omvoh (mirikizumab-mrkz) injection, solution, available in 100 mg/mL and 20 mg/mL strengths, distributed by Eli Lilly and Company.*

FDA Label Image

Figure (Omvoh 200mg Pfs 2)

An instructional illustration of the Omvoh injection device showing its components. The labeled parts include the thumb pad, blue plunger rod, finger grips, gray syringe plunger, syringe body containing the medicine, needle, and removable needle cap, arranged vertically for clear identification.*

FDA Label Image

Figure (Omvoh 200mg Pfs 3)

An illustration showing where the expiration date is located on the barrel of a prefilled syringe. The syringe is white with a blue plunger, and a red circle highlights the expiration date area on the barrel near the needle end.*

FDA Label Image

Figure (Omvoh 200mg Pfs 4)

An instructional illustration showing hands preparing an injection device, specifically demonstrating the removal of a protective cap from a syringe or injection pen, relevant to subcutaneous administration.*

FDA Label Image

Figure (Omvoh 200mg Pfs 6)

An illustration showing the proper technique for subcutaneous injection using an Omvoh autoinjector device. The image depicts a hand holding the device against the skin at an angle, with a red arrow indicating the direction of injection.*

FDA Label Image

Figure (Omvoh 200mg Pfs 7)

An illustration showing a syringe with labeled parts: a blue plunger rod and a gray syringe plunger. The syringe is depicted vertically with the needle pointing downward, highlighting its functional components for administering an injection.*

FDA Label Image

Figure (Omvoh 200mg Pfs 8)

An instructional illustration showing a hand holding a syringe-like injection device above a sharps disposal container, demonstrating proper disposal of a used injection pen or needle into the container.*

FDA Label Image

Package Label – Omvoh 300 mg Vial Carton (Classic Formulation)

Packaging label for Omvoh (mirikizumab-mrkz) injection, 300 mg/15 mL (20 mg/mL) solution for subcutaneous injection. The label includes storage instructions, dosage formulation details, manufacturer Eli Lilly and Company, and a barcode. The product is noted as preservative-free and includes administration guidance for intravenous infusion after dilution.*

FDA Label Image

Package Label – Omvoh 300 mg Vial Carton (Alternate Formulation)

Packaging label for Omvoh (mirikizumab-mrkz) injection, 300 mg/15 mL (20 mg/mL) solution for subcutaneous use. The label includes storage instructions, dosage form, active ingredient strength, manufacturer Eli Lilly and Company, and usage notes such as single-dose vial and disposal guidance. Contains barcodes and regulatory details.*

FDA Label Image

Package Label – Omvoh 100 mg Prefilled Pen (Omvoh Carton 100mg Pen 078 03)

Omvoh 100 mg/mL (mirikizumab-mrkz) injection label for subcutaneous use by Eli Lilly and Company. The carton contains 2 single-dose prefilled pens, each with 1 mL. The label includes product name, strength, dosage form, usage instructions, storage information, and barcode. The label also features images of the pens and directions for dispensing the entire carton as a unit.*

FDA Label Image

Package Label – Omvoh 100 mg Prefilled Syringe (Omvoh Carton 100mg Pfs 100 01)

Omvoh 100 mg/mL (mirikizumab-mrkz) injection carton for subcutaneous use, containing two 1 mL single-dose prefilled syringes. The label notes a total dose of 200 mg per carton with instructions to inject both syringes. The labeler is Eli Lilly and Company. The packaging includes storage instructions, a barcode, and a pharmacy label area.*

FDA Label Image

Package Label – Omvoh 300 mg Prefilled Pen (Omvoh Carton 300mg Pen 109 00)

Packaging label for Omvoh (mirikizumab-mrkz) injection, subcutaneous, available in 200 mg/2 mL and 100 mg/mL strengths. The carton contains two single-dose prefilled pens: one 2 mL pen and one 1 mL pen, totaling 300 mg per carton. Labeler is Eli Lilly and Company. Instructions emphasize dispensing the carton as a single unit and storing refrigerated.*

FDA Label Image

Package Label – Omvoh 300 mg Prefilled Syringe (Omvoh Carton 300mg Pfs 107 00)

Packaging label for Omvoh (mirikizumab-mrkz) injection, a subcutaneous solution available in strengths of 100 mg/mL and 200 mg/2 mL (100 mg/mL). The carton contains two single-dose prefilled syringes (1 mL and 2 mL). The label includes storage instructions, medication information, and a note to pharmacists to dispense the entire carton as a unit. The labeler is Eli Lilly and Company.*

FDA Label Image

Package Label – Omvoh 200 mg Prefilled Syringe (Omvoh Carton 200mg Pen 140 00)

Packaging label for Omvoh (mirikizumab-mrkz) injection, 200 mg/2 mL, a subcutaneous injection. The carton contains one 200 mg/2 mL single-dose prefilled pen. Labeler is Eli Lilly and Company. The label includes storage instructions, medication information, and a barcode. It notes that the carton contains a total dose of 200 mg with only one injection required for a full dose, and advises dispensing an enclosed medication guide to each patient.*

FDA Label Image

Package Label – Omvoh 200 mg Prefilled Syringe (Omvoh Carton 200mg Pfs 139 00)

Packaging label for Omvoh (mirikizumab-mrkz) injection, 200 mg/2 mL (100 mg/mL) single-dose prefilled syringe for subcutaneous use. Label shows the Eli Lilly and Company logo, storage instructions, NDC 0002-1442-11, and a syringe image. The carton contains one prefilled syringe with a total dose of 200 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.